The angiotensin II receptor-neprilysin inhibitor LCZ696 attenuates the progression of proteinuria in type 2 diabetic rats

J Pharmacol Sci. 2020 Mar;142(3):124-126. doi: 10.1016/j.jphs.2019.09.014. Epub 2019 Dec 17.

Abstract

We examined the effects of the angiotensin receptor-neprilysin inhibitor LCZ696 on overt proteinuria and renal injury in type 2 diabetic Otsuka-Long- Evans-Tokushima-Fatty (OLETF) rats. Aged OLETF rats were also treated with either valsartan or valsartan plus hydralazine for comparison. LCZ696 caused greater attenuation of the progression of proteinuria than either valsartan alone or valsartan combined with hydralazine. Reduced glomerular injury and tubulointerstitial fibrosis were also observed in LCZ696-treated rats. Moreover, LCZ696 prevented increases in blood urea nitrogen (BUN) and creatinine levels. These data suggest that LCZ696 elicits a reno-protective effect against type 2 diabetes with overt proteinuria.

Keywords: Diabetic kidney disease (DKD); LCZ696; Proteinuria.

MeSH terms

  • Aminobutyrates / therapeutic use*
  • Angiotensin Receptor Antagonists / therapeutic use*
  • Animals
  • Biphenyl Compounds
  • Diabetes Mellitus, Type 2 / complications*
  • Drug Combinations
  • Proteinuria / drug therapy*
  • Proteinuria / etiology*
  • Rats
  • Rats, Inbred OLETF
  • Tetrazoles / therapeutic use*
  • Valsartan

Substances

  • Aminobutyrates
  • Angiotensin Receptor Antagonists
  • Biphenyl Compounds
  • Drug Combinations
  • Tetrazoles
  • Valsartan
  • sacubitril and valsartan sodium hydrate drug combination